Xeltis Secures €50 Million to Revolutionize Vascular Access with aXess

2025-12-02 bio

Eindhoven, Tuesday, 2 December 2025.
Xeltis has acquired nearly €50 million in funding to commercialize its aXess device, a pioneering vascular access solution, highlighting significant advancements in hemodialysis treatment.

Xeltis: A Leader in MedTech Innovation

Xeltis, a pioneering medtech company headquartered in the Netherlands, has secured nearly €50 million in funding to advance its groundbreaking vascular access device, aXess. This financing includes €37.5 million from the European Investment Bank (EIB), supported by the European Commission’s Invest EU program, and an additional €10 million from existing investors such as EQT and Invest-NL [1][2][3].

The aXess Device: Transforming Vascular Access

The aXess device represents a significant advancement in hemodialysis treatment by enabling the natural growth of living and durable blood vessels. This is achieved through Xeltis’ proprietary Endogenous Tissue Restoration (ETR) platform, which allows the device to be gradually replaced by the patient’s own tissue. This innovative approach combines the safety and durability of arteriovenous fistula (AVF) with the treatment speed of arteriovenous grafts (AVG), offering improved outcomes for patients undergoing hemodialysis [2][4][5].

Funding and Future Plans

The recent funding will facilitate the commercialization of aXess, including scaling up production and expanding Xeltis’ workforce. The company aims to leverage this financial backing to bring its revolutionary vascular access solution to market by 2026, pending European market approval and US pre-market approval. The success of the EU pivotal trial has further validated the device’s potential, showing exceptional improvements in key clinical metrics compared to current standards [1][3][4].

A Collaborative Effort

Xeltis’ achievements underscore the importance of collaboration between public and private entities in advancing medical technology. The European Investment Bank’s substantial investment reflects confidence in Xeltis’ ability to transform medical treatments. Eliane Schutte, CEO of Xeltis, expressed gratitude for the support, highlighting how this partnership accelerates medical progress and strengthens Europe’s leadership in MedTech innovation [1][5][6].

Bronnen

healthtech vascular access